SG11202002665UA - Anti-trkb monoclonal antibodies and methods of use - Google Patents
Anti-trkb monoclonal antibodies and methods of useInfo
- Publication number
- SG11202002665UA SG11202002665UA SG11202002665UA SG11202002665UA SG11202002665UA SG 11202002665U A SG11202002665U A SG 11202002665UA SG 11202002665U A SG11202002665U A SG 11202002665UA SG 11202002665U A SG11202002665U A SG 11202002665UA SG 11202002665U A SG11202002665U A SG 11202002665UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- monoclonal antibodies
- trkb monoclonal
- trkb
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592657P | 2017-11-30 | 2017-11-30 | |
PCT/US2018/062863 WO2019108662A1 (en) | 2017-11-30 | 2018-11-28 | Anti-trkb monoclonal antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002665UA true SG11202002665UA (en) | 2020-04-29 |
Family
ID=64665125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002665UA SG11202002665UA (en) | 2017-11-30 | 2018-11-28 | Anti-trkb monoclonal antibodies and methods of use |
Country Status (16)
Country | Link |
---|---|
US (2) | US11066474B2 (en) |
EP (1) | EP3717514A1 (en) |
JP (2) | JP7438937B2 (en) |
KR (1) | KR20200090779A (en) |
CN (1) | CN111372949A (en) |
AU (1) | AU2018375340A1 (en) |
BR (1) | BR112020006976A2 (en) |
CA (1) | CA3083452A1 (en) |
CL (1) | CL2020000855A1 (en) |
CO (1) | CO2020004075A2 (en) |
EA (1) | EA202090966A1 (en) |
IL (1) | IL273538A (en) |
MA (1) | MA51207A (en) |
MX (1) | MX2020003550A (en) |
SG (1) | SG11202002665UA (en) |
WO (1) | WO2019108662A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US6225282B1 (en) | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2006255101A1 (en) | 2005-06-06 | 2006-12-14 | Wyeth | Anti-TrkB monoclonal antibodies and uses thereof |
EP1988920A1 (en) | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
TW200808352A (en) * | 2006-02-02 | 2008-02-16 | Rinat Neuroscience Corp | Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist |
ATE537190T1 (en) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | HIGH AFFINE ANTIBODIES AGAINST THE HUMAN IL-6 RECEPTOR |
RU2009121641A (en) | 2006-11-09 | 2010-12-20 | Айрм Ллк (Bm) | Agonistic antibodies to TrkB and their application |
KR20090091181A (en) | 2006-12-20 | 2009-08-26 | 리나트 뉴로사이언스 코퍼레이션 | Trkb agonists for treating autoimmune disorders |
CN101980603A (en) | 2007-10-11 | 2011-02-23 | 比奥根艾迪克Ma公司 | Use of LINGO-1 and TrkB antagonists |
JP5420568B2 (en) | 2008-01-17 | 2014-02-19 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Improved anti-TrkB antibody |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
WO2011103667A1 (en) | 2010-02-26 | 2011-09-01 | 6452728 Canada Inc. | Agonistic antibodies to trkb receptors and uses thereof |
GB2491106A (en) | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
US10080745B2 (en) | 2013-11-25 | 2018-09-25 | The Regents Of The University Of California Santa Cruz | Piericidin bacterial inhibitors |
US10392438B2 (en) | 2014-05-16 | 2019-08-27 | Pfizer Inc. | Bispecific antibodies |
US20170029511A1 (en) | 2015-07-28 | 2017-02-02 | Otonomy, Inc. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
CA3005491A1 (en) | 2015-11-17 | 2017-05-26 | Glaxosmithkline Intellectual Property Development Limited | Binding agonists for treatment of neurological and other disorders |
CN109414501A (en) | 2016-05-03 | 2019-03-01 | 斯克利普斯研究院 | For treating the TrkB agonist antibody of neurodegenerative disease |
US9914781B1 (en) | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
US10941203B2 (en) | 2017-03-15 | 2021-03-09 | Tsinghua University | Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma |
-
2018
- 2018-11-28 AU AU2018375340A patent/AU2018375340A1/en active Pending
- 2018-11-28 KR KR1020207014791A patent/KR20200090779A/en unknown
- 2018-11-28 EP EP18819293.4A patent/EP3717514A1/en active Pending
- 2018-11-28 US US16/202,881 patent/US11066474B2/en active Active
- 2018-11-28 SG SG11202002665UA patent/SG11202002665UA/en unknown
- 2018-11-28 JP JP2020517858A patent/JP7438937B2/en active Active
- 2018-11-28 WO PCT/US2018/062863 patent/WO2019108662A1/en unknown
- 2018-11-28 MA MA051207A patent/MA51207A/en unknown
- 2018-11-28 MX MX2020003550A patent/MX2020003550A/en unknown
- 2018-11-28 EA EA202090966A patent/EA202090966A1/en unknown
- 2018-11-28 BR BR112020006976-0A patent/BR112020006976A2/en unknown
- 2018-11-28 CN CN201880069154.2A patent/CN111372949A/en active Pending
- 2018-11-28 CA CA3083452A patent/CA3083452A1/en active Pending
-
2020
- 2020-03-24 IL IL273538A patent/IL273538A/en unknown
- 2020-03-31 CL CL2020000855A patent/CL2020000855A1/en unknown
- 2020-06-03 CO CONC2020/0004075A patent/CO2020004075A2/en unknown
-
2021
- 2021-06-09 US US17/342,749 patent/US20220411515A1/en active Pending
-
2023
- 2023-11-09 JP JP2023191236A patent/JP2024016204A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11066474B2 (en) | 2021-07-20 |
JP2021507677A (en) | 2021-02-25 |
CL2020000855A1 (en) | 2020-07-31 |
KR20200090779A (en) | 2020-07-29 |
EP3717514A1 (en) | 2020-10-07 |
MX2020003550A (en) | 2020-08-03 |
AU2018375340A1 (en) | 2020-05-07 |
CA3083452A1 (en) | 2019-06-06 |
BR112020006976A2 (en) | 2020-10-13 |
CO2020004075A2 (en) | 2020-08-31 |
JP2024016204A (en) | 2024-02-06 |
JP7438937B2 (en) | 2024-02-27 |
EA202090966A1 (en) | 2020-08-26 |
CN111372949A (en) | 2020-07-03 |
US20220411515A1 (en) | 2022-12-29 |
MA51207A (en) | 2020-10-07 |
US20190161551A1 (en) | 2019-05-30 |
WO2019108662A1 (en) | 2019-06-06 |
IL273538A (en) | 2020-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
PL3618863T3 (en) | Anti-tigit antibodies and methods of use thereof | |
ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
IL278772A (en) | Anti-ox40 antibodies and methods of use | |
IL277212A (en) | Anti-klk5 antibodies and methods of use | |
IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
IL268568A (en) | Trailshort antibody and methods of use | |
ZA201805051B (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
IL273538A (en) | Anti-trkb monoclonal antibodies and methods of use | |
ZA202002144B (en) | Antibodies and methods of use |